Blogs Understanding the Amylin Receptor Family: Biology, Function, and Emerging Tools for Drug Discovery

Understanding the Amylin Receptor Family: Biology, Function, and Emerging Tools for Drug Discovery

What Are Amylin Receptors?

Amylin receptors are a family of heterodimeric G protein–coupled receptors (GPCRs) formed by the pairing of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMPs).  The resulting receptor subtypes, AMY1R (CTR + RAMP1), AMY2R (CTR + RAMP2), and AMY3R (CTR + RAMP3), exhibit distinct ligand selectivity and tissue distributions.¹

These receptors bind amylin, a peptide hormone co-secreted with insulin, as well as select peptides from the calcitonin/CGRP family.  Their activation leads to Gαs-mediated increases in intracellular cAMP, linking them to key metabolic, gastrointestinal, and neuroendocrine regulatory pathways.²

FGFR21 Blog Image (2)

The Amylin Receptor Subtypes

AMY1 Receptor (AMY1R)

AMY1R shows high affinity for both amylin and calcitonin gene–related peptide (CGRP), making it functionally relevant in migraine signaling, vasodilation, and neuroendocrine regulation.³  Because RAMP1 is also a component of the canonical CGRP receptor, AMY1R is important when distinguishing CGRP pharmacology from amylin-specific effects.

Physiological and therapeutic relevance:

  • Distinct role in gut–brain axis communication and satiety.⁴
  • Proposed  contribution to CGRP-pathway overlap, with relevance in migraine treatment research.⁵
  • Potential involvement in central sensitization and neuroinflammation.

AMY2 Receptor (AMY2R)

AMY2R binds amylin with high affinity but shows a more restricted tissue pattern, particularly in gastrointestinal and endocrine tissues.⁶  Current opinion suggests a role in  metabolic processes linked to nutrient sensing and digestive regulation.

Physiological and therapeutic relevance:

  • Influencial to gastric emptying and nutrient absorption.⁴
  • Supports glucose homeostasis by modulating meal-ending satiation.
  • Represents a target for metabolic drug discovery, though less characterized than AMY1R and AMY3R.

AMY3 Receptor (AMY3R)

AMY3R is responsive to amylin and exhibits distinct pharmacological behavior due to the presence of RAMP3. It is expressed in the area postrema, gut-brain vagal pathways, and select metabolic regulatory centers.⁷

Physiological and therapeutic relevance:

  • Major contributor to satiety signaling and post-prandial glucose control.⁴
  • Integrates metabolic cues within the CNS, influencing energy homeostasis.⁵
  • Implicated in obesity therapeutics, including dual-agonist and tri-agonist incretin drug development.⁴
  • Explored for roles in Alzheimer’s disease, as amylin and amyloid-β interact with AMY receptors, including AMY3R.⁸
  • Relevant to migraine biology, due to shared pharmacology with CGRP family peptides.⁵

Why Amylin Signaling Matters

Metabolic Regulation

Amylin receptors play a role in reducing food intake, slowing gastric emptying, and modulating glucose responses, making them important targets for anti-obesity and diabetes drug development.⁴

Gut–Brain Axis Integration

The amylin system helps coordinate peripheral metabolic signals with central appetite-regulating circuits.⁵  Dysregulation across receptor subtypes is being investigated in obesity and metabolic syndromes.

Neurodegenerative Disease

Amylin analogs and receptor-modulating compounds are believed to exert neuroprotective effects, influencing amyloid burden and neuronal survival.⁸

Pain and Migraine Biology

Due to pharmacological overlap with CGRP signaling, particularly through AMY1R and AMY3R, amylin pathways are proposed to contribute to headache biology and represent viable targets for next-generation migraine therapeutics.⁵

INDIGO’s Reporter Assays for Amylin Receptors: AMY1R and AMY3R

INDIGO Biosciences is expanding its metabolic and neuroendocrine assay portfolio with two complementary amylin receptor reporter kits:

  • Transiently-transfected AMY3R or AMY1R Reporter Cells
  • cAMP-responsive luciferase readout
  • Ready-to-use assay plate
  • Reference agonist included
  • High sensitivity and reproducibility
  • Available in 96-well, and 3×32-wellformats
  • Ideal for distinguishing amylin vs. CGRP pathway interactions
  • Supports selectivity profiling for migraine and metabolic drug candidates

Both assays leverage INDIGO’s proprietary CryoMite™ cryopreservation technology, allowing researchers to bypass cell culture maintenance and obtain high-quality data in as little as 24 hours.

These assays empower scientists to:

  • Evaluate activation or inhibition activity
  • Compare ligand selectivity across AMY receptor subtypes
  • Screen and optimize lead compounds
  • Support mechanistic studies for incretin-amylin hybrid therapeutics

The amylin receptor family, AMY1R, AMY2R, and AMY3R, plays a role in metabolic regulation, neuroendocrine signaling, and emerging therapeutic strategies for obesity, diabetes, migraine, and neurodegeneration.  With the release of the AMY3R an AMY1R Reporter Assays, INDIGO Biosciences provides researchers with precise and high-performance tools to deepen understanding of amylin pharmacology and accelerate drug discovery.

References

  1. Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015). Amylin: Pharmacology, physiology, and clinical potential. Pharmacological Reviews, 67(3), 564–600.
  2. Sexton, P. M., et al. (2006). Complexing receptor activity-modifying proteins with GPCRs: Modulation of receptor pharmacology and function. Ann N Y Acad Sci., 1070:90-104.
  3. Simms, J.,Routledge, S., Uddin, R., & Poyner, D. (2019). The Structure of the CGRP and Related Receptors. Handbook of Experimental Pharmacology, 255:23-36.
  4. Liberini, C. G., et al. (2019). Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss. Scientific Reports, 9:8447.
  5. Lutz, T. A. (2010). The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol, 298(6), R1475–R1484.
  6. Woolley, M. J. & Conner, A. C. (2013). Comparing the molecular pharmacology of CGRP and adrenomedullin. Curr Protein Pept Sci., 897, 137–148.
  7. Young, A. A. (1997). Amylin’s physiology and its role in diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 4, 282-290.
  8. Zhu, H., et al. (2017). Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease. Neuropharmacology, 119:170-181.